The inhibition of this receptor-ligand interaction using an anti-CTLA-4 antibody results in the reactivation and proliferation of T cells and also decreases the immunosuppressive Treg cells in the tumor microenvironment [4]. The gene discussed is CTLA4; the disease is neoplasm.